JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2000; 35:600-604
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liem, A.
Right arrow Articles by Verheugt, F. W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liem, A.
Right arrow Articles by Verheugt, F. W. A.

CLINICAL STUDIES

High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial

Aylee Liem, MD*, Felix Zijlstra, MD*, Jan Paul Ottervanger, MD*, Jan C. A. Hoorntje, MD*, Harry Suryapranata, MD, FACC*, Menko-Jan de Boer, MD* and Freek W. A. Verheugt, MD, FACC{dagger}

* Hospital De Weezenlanden, Zwolle, the Netherlands
{dagger} University Hospital Nijmegen, Nijmegen, the Netherlands

Manuscript received March 24, 1999; revised manuscript received October 20, 1999, accepted November 15, 1999.

Reprint requests and correspondence: Dr. Felix Zijlstra, Department of Cardiology, Hospital De Weezenlanden, Groot Wezenland 20, 8011 JW Zwolle, the Netherlands.
v.derks{at}diagram-zwolle.nl

OBJECTIVES

In the Heparin in Early Patency (HEAP) pilot study a beneficial effect of high-dose heparin on early patency in acute myocardial infarction (MI) was observed in a matched-control study.

BACKGROUND

High dose bolus intravenous injection of heparin may achieve lysis of coronary thrombi and could enhance early patency of the infarct related vessel in patients with MI scheduled for primary angioplasty.

METHODS

Before primary angioplasty, 584 patients with MI entered an open randomized trial of high dose (300 IU/kg) or low dose (0 or 5,000 IU) heparin. Of the 584 patients, 299 were randomized to high dose and 285 patients to low dose heparin.

RESULTS

Thrombolysis In Myocardial Infarction (TIMI) flow grade 2 or 3 was observed before primary angioplasty in 65 patients (22%) in the high dose group and 60 patients (21%) in the low dose heparin group (p > 0.1), whereas TIMI flow grade 3 was observed in 38 (13%) and 24 patients (9%), respectively (p = 0.11). There were no differences in the clinical end points between the two groups. There were no hemorraghic strokes, while 10% of the patients in the high dose group required blood transfusion versus 6% in the low dose/no heparin group (p = 0.07). No subsets of patients showed beneficial effects of high dose heparin, such as patients with longer delay between heparin administration and diagnostic angiogram or patients with short delay between symptom onset and admission.

CONCLUSIONS

There is no benefit of high dose bolus heparin on early patency compared with no or low dose heparin.

Abbreviations and Acronyms
  HEAP = Heparin in Early Patency
  LDH = lactate dehydrogenase
  LVEF = left ventricular ejection fraction
  MI = myocardial infarction
  TIMI = Thrombolysis In Myocardial Infarction




This article has been cited by other articles:


Home page
ChestHome page
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 708S - 775S.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
Heart, June 1, 2004; 90(6): e37 - e37.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. De Luca, H. Suryapranata, F. Zijlstra, A. W. J. van't Hof, J. C. A. Hoorntje, A. T. M. Gosselink, J.-H. Dambrink, M.-J. de Boer, and ZWOLLE Myocardial Infarction Study Group
Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 991 - 997.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Zijlstra, N. Ernst, M.-J. de Boer, E. Nibbering, H. Suryapranata, J. C. A. Hoorntje, J.-H. E. Dambrink, A. W. J. van't Hof, and F. W. A. Verheugt
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute st elevation myocardial infarction
J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1733 - 1737.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
F. Zijlstra
CORONARY DISEASE: Acute myocardial infarction: primary angioplasty
Heart, June 1, 2001; 85(6): 705 - 709.
[Full Text]


Home page
CirculationHome page
J. P. Collet, G. Montalescot, C. Lesty, Z. Mishal, J. Soria, R. Choussat, G. Drobinski, C. Soria, P. Pinton, P. Barragan, et al.
Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention
Circulation, May 15, 2001; 103(19): 2328 - 2331.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. K. French, T. A. Hyde, I. T. Straznicky, J. Andrews, M. Lund, D. J. Amos, A. Zambanini, C. J. Ellis, B. J. Webber, S. C. McLaughlin, et al.
Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction
J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1516 - 1524.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2000 by the American College of Cardiology Foundation.